newsfilter
← Latest News
PR Newswire·

Ladera Medical Presents Full FASTEN Results Showing Rapid Hemostasis and a Strong Safety Profile with its Large Bore Closure System

  • Ladera Medical announced full results from the FASTEN clinical trial of its Large Bore Closure System at London Valves 2026.
  • Data was presented by Dr. Jan van der Heyden from a prospective, multicenter, single-arm study involving 55 patients across six sites in Australia, Belgium, & the Netherlands.
  • The study achieved a mean time to hemostasis of 0.5 ± 2.0 minutes with a median of 0 minutes.
  • Freedom from major access-site complications at 30 days was 98.1% (52 out of 53 patients).
  • Freedom from minor access-site complications at 30 days was also 98.1% (52 out of 53 patients).
  • Technical success was recorded at 94.5% (52 out of 55 patients), while treatment success was 94.3% (50 out of 53 patients).
  • The mean time to ambulation was 14.3 ± 14.5 hours.
  • The Ladera System utilizes a unique mechanism to deploy two parallel sutures simultaneously for closure of 10F to 24F arteriotomies.
  • The device allows for pre-close or post-close deployment while maintaining guidewire access throughout the procedure.
  • The system is limited by Federal law to investigational use & is not available for sale in any country.
Company
Ladera Medical, Inc / SPRIG CONSULTING, LLC
Keywords
Ladera Medical, Inc / SPRIG CONSULTING, LLC